Embera NeuroTherapeutics, Inc. is a clinical-stage pharma company based in Shreveport, La., and Boston, Mass., focused on smoking cessation, cocaine dependence
EMB-001’s clinical efficacy has been successfully demonstrated in a published pilot study in cocaine-dependent human subjects. In addition, efficacy against nicotine, cocaine, and methamphetamine dependence has been shown in published preclinical studies. In the nicotine dependence preclinical study, EMB-001 was shown to be significantly more effective than Chantix®, Pfizer’s $648M smoking cessation product
Embera’s cocaine-dependence product addresses a disease with no approved treatments today. EMB-001 is currently the most advanced product in clinical development. A Phase 1 safety and pharmacokinetic study is underway in smokers that will enable Phase 2 development programs in smoking cessation and cocaine dependence. Embera’s development programs have been supported by Shreveport-area investors, including the New Louisiana Angel Fund, Louisiana Ventures, Themelios Ventures
Visit Embera’s Website
The Entrepreneurial Accelerator Program (EAP) helps create wealth for entrepreneurs by analyzing viable ideas and products, matching them with informed investors, and nurturing them toward rewarding markets.